Xinfan Huang

Amkey Ventures LLC (Amkey Ventures) is a venture capital firm founded in 2001 by George J. Lee and Woody Sing-Wood Yeh. The firm headquartered in Fremont, California.

Part of Applied BioCode Corp., Applied BioCode, Inc. is a diagnostic testing company that designs, develops, and commercializes multiplex testing products. The company is based in Santa Fe Springs, CA. Applied BioCode offers a range of diagnostic assays, including the BioCode SARS-CoV-2 assay, the BioCode Respiratory Pathogen Panel, and the BioCode Gastrointestinal Pathogen Panel. The company's technology combines "digital barcodes" with immuno- and molecular chemistry to create a new, bio-inspired Barcoded Magnetic Beads (BMB) technology. The micro BMBs are about the diameter of a human hair and are the ideal choice for cost-effective high throughput syndromic panels. The company was founded in 2008 by Winston Z. Ho, and Christopher M. Bernard has been the CEO of the company since 2022.

Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation.

RevMAb Biosciences, Inc. operates as a biotechnology company. It focuses on the development of monoclonal antibodies using a revolutionary technology that does not require cell fusion and hybridoma generation. The company is headquartered in South San Francisco, CA.

Part of Munir Sukhtian Pharmaceuticals, GenePharm Biotech Corp. develops and commercializes preventive and curative therapeutics for skin-related problems. The company is based in Xizhi District, Taiwan.

Crown Bioscience, Inc. provides biomedical outsourcing solutions. It provides syngeneic and xenograft tumor models and custom model development and drug testing. The firm produces antibodies for therapeutic, diagnostic and theranostic applications. It also offers preclinical and drug development for anti-cancers therapeutics. The company was founded by Dr. Yiyou Chen, Dr. Yue Alexander Wu, Dr. William Pan and Dr. Faming Zhang in 2006 and is headquartered in Santa Clara, CA.

Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA.

Cardiva Medical, Inc. designs and develops vascular access management products. It offers VASCADE, an extravascular closure device designed to increase the comfort and safety of vascular closure for patients; and Catalyst, a device that supports the body's natural healing process by enhancing the vessel's inherent natural elastic recoil, tissue apposition and coagulation. The company was founded by Zia Yassinzadeh and Augustine Y. Lien in July 2002 and is headquartered in Santa Clara, CA.

StemCyte, Inc. operates as a biotechnology company that collects, banks and distributes cord blood stem cell transfusion units. It focuses on stem cell transplantation, therapy, applications, diagnostics, and genomic research. The firm uses insulated containers to keep your baby's cord blood cool throughout transport. The company was founded by Denis Rodgerson and Robert Chow in 1997 and is headquartered in Covina, CA.

Biokey, Inc. develops and markets generic drugs. Its services include regulatory support, analytical services, product development, and GMP manufacturing. The company was founded by George J. Lee in 2001 and is headquartered in Fremont, CA.

Epitomics, Inc. an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb®) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics. Compared to currently available monoclonal antibody technology, such as mouse hybridomas, the company's proprietary technology can generate RabMAbs more efficiently and with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle. The company aims to become the largest provider of monoclonal antibody technology through developing and commercializing their RabMAb technology and products in research, diagnostics, and therapeutics. The firm is headquartered in Burlingame, California and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.